J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Non-Hodgkin lymphoma of the prostate
John Steuter,Dennis D. Weisenburger,R. Greg Bociek,Philip J. Bierman,Julie M. Vose,Martin Bast,Fausto R. Loberiza,James O. Armitage +7 more
TL;DR: In this paper, the authors proposed a method to solve the problem of "no abtract" and "No abtraction" of the problem: "No Abtract".
Journal ArticleDOI
Safety and efficacy of axicabtagene ciloleucel (axi-cel) in older patients: results from the us lymphoma car-t consortium
Dahlia Sano,Lazaros J. Lekakis,Li Feng,L. J. Nastoupil,Michael D. Jain,Jay Y. Spiegel,Saurabh Dahiya,Yi Lin,A. Ghobadi,Matthew A. Lunning,Brian T. Hill,Patrick M. Reagan,Olalekan O. Oluwole,Joseph P. McGuirk,Alison R. Sehgal,Abhinav Deol,A. Charalambos,Andre Goy,Javier Munoz,Amanda F. Cashen,Nora N Bennani,Aaron P. Rapoport,Julie M. Vose,David B. Miklos,Frederick L. Locke,S.S. Neelapu +25 more
TL;DR: This work presents a meta-analyses of Kite’s and Novartis’ Comparative Anatomy of Immune Design and showed clear trends in progenitor cell reprograming that are consistent with those observed in previous studies of T-cells reprogramed for wound healing.
Journal ArticleDOI
Building Bridges for Collective Wisdom.
Peter Paul Yu,Julie M. Vose +1 more
TL;DR: The first issue of Journal of Global Oncology (JGO), ASCO’s new online-only, open-access journal dedicated to publishing the highest quality information concerning oncology research and care delivery in countries with limited health care resources, is published.
Journal ArticleDOI
Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma
Radwa El Behery,Javier A. Laurini,Dennis D. Weisenburger,Lynette M. Smith,Bhavana J. Dave,Jane Yuan,Kai Fu,Wing C. Chan,Bharat N. Nathwani,P. J. Bierman,Robert G. Bociek,Julie M. Vose,James O. Armitage,Timothy C. Greiner,Patricia Aoun +14 more
TL;DR: F follicular large cleaved cell lymphoma (FLC) is a variant of follicular lymphoma which should be recognized in future lymphoma classifications because the diagnosis of FLC may be important for the selection of therapy.
Journal ArticleDOI
Combination of tgr‐1202, ublituximab, and bendamustine is safe and highly active in patients with advanced dlbcl and follicular lymphoma.
Matthew A. Lunning,Julie M. Vose,P. J. Bierman,Gregory Bociek,M.T. Schreeder,Tanya Siddiqi,Susan Blumel,K. Cutter,E.K. Pauli,D. Bui,Peter Sportelli,Hari P. Miskin,M. Purdom,Michael S. Weiss,Nathan Fowler +14 more
TL;DR: Presented at the 14th International Conference on Malignant Lymphoma, June 14 – 17, 2017, Lugano, Switzerland.